NKTR News and Press, Nektar Therapeutics From 11/07/23

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

Nektar Therapeutics (NKTR) is expected to report $-0.18 for Q3 2023

Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets PR Newswire SAN FRANCISCO , Oct. 31, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial resu...

Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress PR Newswire – Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rap...

Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy PR Newswire – Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be...

2023-09-27 12:47:12 ET More on Nektar Therapeutics Nektar Therapeutics (NKTR) Q2 2023 Earnings Call Transcript Data Errors Could Give Nektar Therapeutics A New Lease On Life Nektar reportedly sues Lilly for bungling clinical data on dermo drug Seeking Alpha&#...

Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer PR Newswire SAN FRANCISCO , Sept. 27, 2023 /PRNewswire/ -- Nektar Therapeu...

Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis PR Newswire New Statistically Significant Results Reported for Clinical Efficacy Endpoints of BSA, DLQI and POEM from Phase 1b Study ...

2023-09-11 14:22:11 ET Penny stocks priced under $1 per share have attracted a dedicated following among traders seeking massive returns. While penny stocks are inherently high-risk investments, the potential reward with these low-priced shares is exponentially higher compared to tradit...

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th PR Newswire SAN FRANCISCO , Sept. 6, 2023 /...